Oncology | Phase II Developments | SPAIN

Highlight Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Highlight Therapeutics Announces First Patient Dosed in Phase IIa Study in Liver Metastasis

Lead Product(s): BO-112,Pembrolizumab

Therapeutic Area: Oncology Product Name: BO-112

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2020

Details:

Highlight Therapeutics dosed first patient in a Phase IIa clinical evaluation of the combination of BO-112, Highlight's lead program, and KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with select advanced stage solid tumors with liver metastases.

Oryzon Genomics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

ORYZON to Present Additional Efficacy Clinical Data From ALICE Phase IIa Trial with Iadademstat

Lead Product(s): Iadademstat,Azacitidine

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2020

Details:

ALICE is a single arm, open-label Phase IIa clinical trial to evaluate the safety, tolerability, dose finding and efficacy of iadademstat in combination with azacitidine in older patients with AML in first line therapy.

PharmaMar

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

PharmaMar, Jazz Pharma Announce FDA Acceptance and Priority Review of NDA for Lurbinectedin in Relapsed Small Cell Lung Cancer

Lead Product(s): Lurbinectedin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: February 17, 2020

Details:

PharmaMar submitted the NDA to FDA in December 2019 based on data from the Phase II monotherapy basket trial, which included evaluation of lurbinectedin for the treatment of relapsed SCLC.

PharmaMar

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

PharmaMar announces the initiation of a study of lurbinectedin in combination with immunotherapy

Lead Product(s): Lurbinectedin,Atezolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: January 14, 2020

Details:

PharmaMar to start a Phase I-II study to determine the recommended dose and efficacy of lurbinectedin in combination with atezolizumab in patients with advanced Small Cell Lung Cancer (SCLC).

Find

Find Oncology Drugs in Phase II Clinical Development in SPAIN

Spain

Product Type

Companies

Highlight Therapeutics

Highlight Therapeutics Announces First Patient Dosed in Phase IIa Study in Liver Metastasis

Oryzon Genomics

ORYZON to Present Additional Efficacy Clinical Data From ALICE Phase IIa Trial with Iadademstat

PharmaMar

PharmaMar, Jazz Pharma Announce FDA Acceptance and Priority Review of NDA for Lurbinectedin in Relapsed Small Cell Lung Cancer

PharmaMar

PharmaMar announces the initiation of a study of lurbinectedin in combination with immunotherapy